Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) ROCE %: -49.56% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
9 GF Score
Price HK$7.60
! 2 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co ROCE %?

Guangzhou Innogen Pharmaceutical Group Co HKSE:02591 +5.26% 9 ROCE % is -49.56% as of Dec. 2025. GuruFocus rates HKSE:02591 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Guangzhou Innogen Pharmaceutical Group Co's annualized ROCE % for the quarter that ended in Dec. 2025 was -49.56%.

Guangzhou Innogen Pharmaceutical Group Co  (HKSE:02591) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Guangzhou Innogen Pharmaceutical Group Co ROCE % Related Terms

Guangzhou Innogen Pharmaceutical Group Co ROCE % Historical Data

* Premium members only.

The historical data trend for Guangzhou Innogen Pharmaceutical Group Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Guangzhou Innogen Pharmaceutical Group Co ROCE % Chart

Guangzhou Innogen Pharmaceutical Group Co Annual Data
Trend Dec23 Dec24 Dec25
ROCE %
-98.00 -22.27 -36.99

Guangzhou Innogen Pharmaceutical Group Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % 0.00 -19.63 -24.96 -33.09 -49.56
HKSE:02591
9GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Innogen Pharmaceutical Group Co ROCE % Calculation

Guangzhou Innogen Pharmaceutical Group Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-375.215/( ( (998.06 - 147.613) + (1735.535 - 557.427) )/ 2 )
=-375.215/( (850.447+1178.108)/ 2 )
=-375.215/1014.2775
=-36.99 %

Guangzhou Innogen Pharmaceutical Group Co's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-480.778/( ( (1026.265 - 264.212) + (1735.535 - 557.427) )/ 2 )
=-480.778/( ( 762.053 + 1178.108 )/ 2 )
=-480.778/970.0805
=-49.56 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -49.56% mean?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a ROCE % of -49.56% as of Dec. 2025.
Is Guangzhou Innogen Pharmaceutical Group Co's ROCE % too high?
Guangzhou Innogen Pharmaceutical Group Co's current ROCE % is -49.56%. Overall, Guangzhou Innogen Pharmaceutical Group Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Guangzhou Innogen Pharmaceutical Group Co's ROCE % compare to VRTX and REGN?
Guangzhou Innogen Pharmaceutical Group Co's ROCE % of -49.56% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Guangzhou Innogen Pharmaceutical Group Co's current ROCE % is -49.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangzhou Innogen Pharmaceutical Group Co stock overvalued right now?
Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) has a current ROCE % of -49.56%. The current ROCE % is -49.56%. Guangzhou Innogen Pharmaceutical Group Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591), the current ROCE % is -49.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
9GF Score

Get the complete analysis for HKSE:02591

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$7.60
Price